{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"BioMarin Pharmaceutical Inc."},"Symbol":{"label":"Symbol","value":"BMRN"},"Address":{"label":"Address","value":"770 LINDARO STREET, SAN RAFAEL, California, 94901, United States"},"Phone":{"label":"Phone","value":"+1 415 506-6700"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) is poised to potentially launch in the 2022-23 timeframe."},"CompanyUrl":{"label":"Company Url","value":"https://www.biomarin.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Alexander Hardy","title":"President, Chief Executive Officer & Director"},{"name":"C. Greg Guyer","title":"Chief Technical Officer & Executive Vice President"},{"name":"Eduardo E. von Pervieux","title":"Chief Information Officer"},{"name":"Gregory Friberg","title":"Executive VP, Chief Research & Development Officer"},{"name":"Kevin Eggan","title":"Group VP, Head-Research & Early Development"},{"name":"Stuart Bunting","title":"Vice President & Head-Research"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}